Physician profile
Audra Albert
NPI 1902156680
$1,455.16
in general payments reported to CMS, 2019-2025
15 companies · $175 in 2025
The $175 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $270 · 2022: $212 · 2023: $424 · 2024: $374 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $900 · Education: $72.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $900.44 |
| Education | $72.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $553.05 | 2021-2025 | Tavneos, Enbrel, Evenity |
| Pfizer INC. | $229.30 | 2021-2025 | |
| Abbvie INC. | $175.64 | 2022-2023 | |
| Lilly USA, LLC | $86.40 | 2021-2024 | Taltz |
| Janssen Biotech, INC. | $82.62 | 2021-2024 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $69.39 | 2022-2024 | Saphnelo |
| Fidia Pharma USA INC. | $58.04 | 2024-2025 | Hymovis, Triluron, Hyalgan |
| Novartis Pharmaceuticals Corporation | $47.13 | 2024-2025 | |
| Ucb, INC. | $26.87 | 2024 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.71 | 2024 | Ofev |
| E.R. Squibb & Sons, L.L.C. | $23.81 | 2025 | Orencia |
| Celgene Corporation | $22.85 | 2024 | Orencia |
| Aurinia Pharma U.S., INC. | $21.71 | 2025 | Lupkynis |
| Sandoz INC. | $19.44 | 2025 | Hyrimoz |
| Genentech USA, INC. | $13.20 | 2024 | Actemra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audra Albert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.